Congress

Politics By Lev Facher

Covid-19 relief package likely to include billions more for vaccines, testing

Politics By Damian Garde

Pharma promises lawmakers, again and again, industry won’t cut corners with Covid-19 vaccines

Politics By Lev Facher

Many drug companies working on Covid-19 vaccines and treatments are lobbying harder than usual

Politics By Damian Garde

Two lawmakers own large sums of stock in vaccine makers set to testify before their committee

Pharmalot By Ed Silverman

Pharmalittle: FDA to issue guidance on Covid-19 vaccines; what remdesivir pricing may really mean

Politics By Lev Facher

Trouble in paradise: The Senate’s bipartisan accord on drug prices is broken, says Grassley 

Politics By Nicholas Florko

Lawmakers, government watchdog blast FDA for poor oversight of U.S. drug supply chain

Politics By Lev Facher

Debate over hydroxychloroquine spills over from the White House to congressional campaigns

First Opinion By Andy Slavitt and Farzad Mostashari

Covid-19 is battering independent physician practices. They need help now

Health Tech By Rebecca Robbins

Federal legislation to protect health data has made little progress. Will that change in the Covid-19 era?

Politics By Nicholas Florko

Rick Bright is facing attacks from Republicans across Washington, but his opponents can’t seem to land a punch

Exclusive By Nicholas Florko and Matthew Herper

Biotech’s new chief lobbyist says she’s a social justice advocate. Will the industry walk the walk?

By Lev Facher

6 takeaways from the Senate’s surreal virtual hearing on the U.S. coronavirus response

Health Tech By Casey Ross

Telehealth rules have shifted rapidly during the pandemic. Are the changes here to stay?

Politics By Lev Facher

A bipartisan group of former health officials seeks to sell a $46.5 billion coronavirus plan to the White House

Politics By Lev Facher

General Motors, 3M, and pharma companies beef up lobbying firepower amid coronavirus pandemic

Politics By Nicholas Florko

This tiny federal agency was built to respond to a crisis like coronavirus. Now that it’s here, is BARDA ready?

Politics By Lev Facher

Lawmakers’ coronavirus response means delays for drug pricing legislation

Politics By Nicholas Florko

Congress set to overhaul the way the U.S. regulates over-the-counter drugs

Pharmalot By Ed Silverman

Preventing other Shkreli-like debacles may not save the government much money

Pharmalot By Ed Silverman

A quarantined Ted Cruz proposes to speed approvals for coronavirus drugs and vaccines

Politics By Lev Facher

Washington, the world’s handshake capital, adjusts to life in the coronavirus era

Politics By Lev Facher

Private equity firms are increasingly buying up doctors’ offices. What does that mean for doctors — or for patients?

Politics By Nicholas Florko

Congress asked the FDA to explain its rules on CBD — but its new report offers little clarity

Politics By Nicholas Florko

Progressives push Trump administration to ensure a future coronavirus vaccine is affordable